THZ-1

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种有效的、选择性的、共价 CDK7 抑制剂，IC50 为 3.2 nM；还弱抑制 CDK12，IC50 为 250 nM；对癌细胞系子集显示出广泛的活性，IC50 小于 200 nM。

A potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM; displays broad-based activity a subset of cancer cell lines with IC50s of <200 nM; causes decreased cellular proliferation and an increase in apoptotic index (MCL-1, XIAP), disproportionally affects transcription of RUNX1 in Jurkat T-ALL cells; demonstrates efficacy against primary leukemia cells and in a bioluminescent xenografted model at 10mg/kg.

——

——

CDK7 inhibitor

Angiogenesis

CDK

CDK7

Cancer

——

1604810-83-4

566.0527

C31H28ClN7O2

>98% (HPLC)

DMSO: ≥ 27 mg/mL

CN(C)CC=CC(=O)NC1=CC=C(C=C1)C(=O)NC2=CC=CC(=C2)NC3=NC=C(C(=N3)C4=CNC5=CC=CC=C54)Cl

Benzamide, N-[3-[[5-chloro-4-(1H-indol-3-yl)-2-pyrimidinyl]amino]phenyl]-4-[[(2E)-4-(dimethylamino)-1-oxo-2-buten-1-yl]amino]-

(-20℃)

With Ice Pack

≥ 2 years